| Literature DB >> 34476248 |
Christina Hoffmann1, Uta Liebers1, Philipp Humbsch1, Marija Drozdek1, Georg Bölke1, Peter Hoffmann1, Adrien Holzgreve1,2, Gavin C Donaldson3, Christian Witt1.
Abstract
BACKGROUND: Patients with respiratory diseases are vulnerable to the effects of heat. Therefore, it is important to develop adaptation strategies for heat exposure. One option is to optimise the indoor environment. To this end, we equipped hospital patient rooms with radiant cooling. We performed a prospective randomised clinical trial to investigate potentially beneficial effects of the hospitalisation in rooms with radiant cooling on patients with a respiratory disease exacerbation.Entities:
Year: 2021 PMID: 34476248 PMCID: PMC8405870 DOI: 10.1183/23120541.00881-2020
Source DB: PubMed Journal: ERJ Open Res ISSN: 2312-0541
FIGURE 1Study flow chart.
Characteristics of the different patient cohorts hospitalised in rooms with or without radiant cooling
|
|
|
|
|
| 20 | 42 | – | |
| 9 (45.0) | 11 (26.2) | 0.139 | |
| 65 (48–84) | 66 (32–85) | 0.757 | |
| 23 (17–53) | 27 (16–42) | 0.024* | |
| – | 10.3# | 0.320 | |
| 83.3¶ | 79.5# | 0.320 | |
| 16.7¶ | 10.3# | 0.320 | |
| COPD | 19 (95.0) | 37 (88.1) | 0.390 |
| GOLD 1 | – | 5.9+ | 0.496 |
| GOLD 2 | 14.3§ | 20.6+ | 0.496 |
| GOLD 3 | 35.7§ | 44.1+ | 0.496 |
| GOLD 4 | 50.0§ | 29.4+ | 0.496 |
| GOLD A | – | – | 0.563 |
| GOLD B | 50.0§ | 40.0+ | 0.563 |
| GOLD C | – | – | 0.563 |
| GOLD D | 50.0§ | 60.0+ | 0.563 |
| Asthma | 3 (15.0) | 7 (16.7) | 0.868 |
| Pulmonary hypertension | 4 (20.0) | 3 (7.1) | 0.135 |
| Interstitial lung disease | 2 (10.0) | 2 (4.8) | 0.433 |
| Pneumonia | 7 (35.0) | 6 (14.3) | 0.061 |
| Neoplasia | 1 (5.0) | 1 (2.4) | 0.585 |
Comparisons were made by chi-squared test or Mann–Whitney U-test. *p<0.05. BMI: body mass index; GOLD: Global Initiative for Chronic Obstructive Lung Disease. #Three patients did not disclose their smoking status, valid percent, adds up to more than 100% due to rounding error. ¶Two patients did not disclose their smoking status, valid percent is reported. +Missing data for 8 patients, valid percent. §Missing data for 6 patients, valid percent.
FIGURE 2Length of hospital stay in each group. The upper panel a) illustrates the length of hospital stay in the conventional patient rooms. The lower panel b) shows the hospitalisation duration in the rooms with radiant cooling.
Comparison of patients’ length of stay, clinical status, and body weight dynamics depending on the air conditioning status of the patient rooms
|
|
|
|
|
| 9 days (3–18) | 6 days (3–14) | 0.003 | |
|
| |||
| Admission | 27 (15–36) | 28 (11–38) | 0.556 |
| Discharge | 23 (1–32) | 23 (6–36) | 0.864 |
|
| |||
| Admission | 3 (1–4) | 4 (0–4) | 0.176 |
| Discharge | 3 (0–4) | 3 (0–4) | 0.812 |
|
| |||
| Admission | 61 kg (44–152) | 80 kg (48–138) | 0.002** |
| Discharge | 61 kg (44–100) | 76 kg (46–110) | 0.049* |
CAT: COPD Assessment Test; mMRC: Modified British Medical Research Council Questionnaire for Dyspnoea. * p<0.05; ** p<0.01.
Comparison of the clinical status and body weight dynamics between admission and discharge of the patients
|
|
|
|
|
|
| |||
| Room without cooling | 27 (15–36) | 23 (1–32) | 0.016* |
| Room with cooling | 28 (11–38) | 23 (6–36) | 0.001** |
|
| |||
| Room without cooling | 3 (1–4) | 3 (0–4) | 1.000 |
| Room with cooling | 4 (0–4) | 3 (0–4) | 0.149 |
|
| |||
| Room without cooling | 61 kg (44–152) | 61 kg (44–100) | 0.715 |
| Room with cooling | 80 kg (48–138) | 76 kg (46–110) | 0.102 |
CAT: COPD Assessment Test; mMRC: Modified British Medical Research Council Questionnaire for Dyspnoea.
* p<0.05; ** p<0.01.
Results of mixed-effects regression modelling
|
|
| ||||
|
|
|
|
|
| |
|
| 0.270 | 0.064 | 0.083 | 0.155 | 0.002** |
|
| |||||
| Systolic | <0.001*** | <0.001*** | 0.044* | 0.001** | <0.001*** |
| Diastolic | <0.001*** | <0.001*** | 0.623 | 0.089 | 0.162 |
|
| <0.001*** | 0.415 | 0.081 | 0.768 | 0.760 |
|
| 0.071 | 0.471 | 0.645 | 0.258 | 0.163 |
|
| 0.090 | <0.001*** | 0.010* | 0.141 | <0.001*** |
|
| <0.001*** | <0.001*** | 0.083 | 0.797 | <0.001*** |
BMI: body mass index; Smoking status: smoker/former smoker/non-smoker. #Measured in the morning with an ear thermometer. ¶Measured in the morning. * p<0.05; ** p<0.01; *** p<0.001.
FIGURE 3Activity tracking results. Displayed are mean values of step counts (dots) and 95% confidence intervals (whiskers). The activity data originate from the following number of patients: day 1, n=9; day 2, n=10; day 3, n=18; day 4, n=16; day 5, n=13; day 6, n=10; day 7, n=9.
Patients’ medication by room type
|
|
|
|
|
| 12 (60) | 33 (79) | 0.205 | |
| 13 (65) | 28 (67) | 0.892 | |
| 8 (40) | 26 (62) | 0.149 | |
| 5 (25) | 11 (26) | 0.992 | |
| 9 (45) | 27 (64) | 0.213 | |
| 12 (60) | 15 (36) | 0.046* | |
| 1 (5.0) | 11 (26) | 0.057 | |
| 0 (0.0) | 2 (4.8) | 0.333 | |
| 1 (5.0) | 7 (17) | 0.222 | |
| 12 (60) | 8 (19) | 0.001** | |
|
| 7 (35) | 13 (31) | 0.650 |
|
| 9 (45) | 20 (48) | 0.986 |
Comparisons were made by chi-squared test. LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist; SABA: short-acting beta2-agonist; SAMA: short-acting muscarinic antagonist; ICS: inhaled corticosteroid; ACE: angiotensin-converting enzyme. * p<0.05; ** p<0.01.